Meeting
2017 ASCO-SITC Clinical Immuno-Oncology Symposium
Activity of CBT-501, a novel humanized anti-PD-1 antibody, in a humanized genetically engineered mouse model of colon carcinoma.
Authors
Qing Zhou
Genor Biopharma Co., Ltd., Shanghai, China
Qing Zhou, Weihong Nian, Ziyong Sun, Junzhuan Qiu, Zhun Wang, Gavin Choy, Sanjeev Redkar
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A
Track
Biomarkers and Inflammatory Signatures,Humoral Immunity for Diagnosis and Therapy,Immune Checkpoints and Stimulatory Receptors,Modulating Innate Immunity,Therapies Targeting T cells
Sub Track
Novel Immune Checkpoints
Citation
J Clin Oncol 35, 2017 (suppl 7S; abstract 108)
DOI
10.1200/JCO.2017.35.7_suppl.108
Abstract #
108
Poster Bd #
F7
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
IFN-α, IFN-γ, IL-2 combined with TNF-α for predicting efficacy of PD-1 inhibitors combination therapy in patients with solid cancers.
First Author: Penghui Xing
Poster
2014 ASCO Annual Meeting
Combination between a long-acting engineered cytokine (NKTR-214) and checkpoint inhibitors anti-CTLA-4 or anti-PD1 in murine tumor models.
First Author: Seema S. Kantak
Poster
2023 ASCO Gastrointestinal Cancers Symposium
RELATIVITY-106: A phase 1/2 trial of nivolumab (NIVO) + relatlimab (RELA) in combination with bevacizumab (BEV) in first-line (1L) hepatocellular carcinoma (HCC).
First Author: Bruno Sangro
Poster
2022 ASCO Annual Meeting
Antitumor activity of T cells expressing a novel anti-folate receptor alpha (FOLR1) costimulatory antigen receptor (CoStAR) in a human xenograft murine solid tumor model and implications for in-human studies.
First Author: Owen R. Moon